Adding Chemotherapy to Endocrine Therapy After Surgery in Women Aged ≥70 Years With ER+/HER2− Breast Cancer and a High Genomic Grade Index
Journal of Clinical Oncology
TAKE-HOME MESSAGE
This phase III trial showed no statistically significant overall survival (OS) benefit with the addition of chemotherapy to endocrine therapy (ET) after surgery in patients older than 70 years with ER+, HER2− breast cancer with a high tumor genomic grade index (GGI).
GGI is not predictive of OS benefits with chemotherapy added to ET in this patient population.
– Jing Xi, MD, MPH
Written by
Hazelgreen
To view profiles and participate in discussions please or .
By chemotherapy did they mean oral or IV meds? I also hold the view from personal experience that “strong” chemo can be harmful to older people, especially with long term side effects. It would be a tough call though to not offer someone a treatment that is out there, I think most people would want to try whatever is in the arsenal.
The chemotherapy provided was: "Investigators chose between 3 CT regimens: 4 cycles of doxorubicin/cyclophosphamide, non-pegylated liposomal doxorubicin/cyclophosphamide or docetaxel/cyclophosphamide, given q3w with G-CSF." These choices were compared to: "Standard ET consisted of 5 years of aromatase inhibitor, tamoxifen or a sequence based on tolerance."
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.